Lykos CEO steps down after MDMA is rejected by FDA
The fallout from the FDA's recent decision not to approve Lykos Therapeutics' psychedelic treatment has spread to its senior management, with chief executive Amy Emerson stepping down.
Newsletters and Deep Dive digital magazine
The fallout from the FDA's recent decision not to approve Lykos Therapeutics' psychedelic treatment has spread to its senior management, with chief executive Amy Emerson stepping down.
AstraZeneca has confirmed that some of its current and former employees have been taken into custody in China as part of an investigation into data privacy breaches and the import of unlice
For the sixth year running the PM Society will be bringing their ‘A Career in Pharmaceutical and Healthcare Communications’ event back to the Royal Society of Medicine.
In a bid to put litigation over the safety of its talc products into the rearview mirror, Johnson & Johnson has added another $1.1 billion to its settlement offer, according to media re
There's been another twist to the tale of Advanz Pharma's efforts to keep its primary biliary cholangitis (PBC) therapy Ocaliva on the market in the EU.
Editor's Picks
Newsletters and Deep Dive
digital magazine